rituximab

Audio Journal of Oncology in Advance – March 15th, 2008+

16th March 2008

Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York

david maloney Audio Journal of Oncology in Advance   March 15th, 2008
David Maloney

Nonmyeloablative

Read More+

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?+

27th February 2008

timothy illidge Radio Labelled Antibodies: Big Benefits in Follicular Lymphoma?
Timothy Illidge

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim

Read More+

Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma+

26th February 2008

martin dreyling Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
Martin Dreyling

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He

Read More+

Chronic Lymphocytic Leukemia After Fludarabine Failure+

26th February 2008

john gribben Chronic Lymphocytic Leukemia After Fludarabine Failure
John Gribben

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as

Read More+

ASCO Audio Journal of Oncology in Advance – February 1st, 2007 – reporting from American Society of Hematology 48th Annual Meeting, December 9-12, 2006 Orlando+

3rd February 2007

frank giles ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Francis Giles
ken kaushansky ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Ken Kaushansky
heather leitch ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Heather Leitch
nancy berliner ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Nancy Berliner
corrado tarella ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Corrado Tarella
vincent rajkumar ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Vincent Rajkumar
robert kyle ASCO Audio Journal of Oncology in Advance   February 1st, 2007   reporting from American Society of Hematology 48th Annual Meeting, December 9 12, 2006 Orlando
Robert Kyle

Aurora Kinase BCR-ABL Inhibitor Beats T315-I Mutation in Patients with Chronic Myeloid Leukemia

REFERENCE: Abstract: 163
FRANCIS GILES, M D Anderson Cancer Center, Houston
COMMENT: KEN

Read More+

ASCO Audio Journal of Oncology in Advance – December 15th, 2006 – Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9-12, 2006+

16th December 2006

martin muller ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Martin Müller
charles linker ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Charles Linker
andreas hochhaus ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Andreas Hochhaus
christian buske ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Christian Buske
katarina leblanc ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Katarina Le Blanc
stephen emerson ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Stephen Emerson
alessandro vannucchi ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Alessandro Vannucchi
kanti rai 1 ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Kanti Rai
richard schlenk ASCO Audio Journal of Oncology in Advance   December 15th, 2006   Reporting from the American Society of Hematology 48th Annual Meeting, Orlando, Florida, December 9 12, 2006
Richard Schlenk

BCR-ABL Mutations After Imatinib Failure: Impact on Response to Dasatinib

REFERENCE: American Society of Hematology 2006 Orlando: Abstract: 748
MARTIN MÜLLER,

Read More+

Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma+

21st December 2005

sandra horning Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma
Sandra Horning

Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction …

Read More+